Immunocore Holdings Future Growth
Future criteria checks 1/6
Immunocore Holdings is forecast to grow earnings and revenue by 34.9% and 16.7% per annum respectively. EPS is expected to grow by 31.8% per annum. Return on equity is forecast to be -48.4% in 3 years.
Key information
34.9%
Earnings growth rate
31.8%
EPS growth rate
| Biotechs earnings growth | 26.7% |
| Revenue growth rate | 16.7% |
| Future return on equity | -48.4% |
| Analyst coverage | Good |
| Last updated | 19 Dec 2024 |
Recent future growth updates
Recent updates
There Is A Reason Immunocore Holdings plc's (NASDAQ:IMCR) Price Is Undemanding
Jan 08
Immunocore Is Adequately Valued, But Its Prospects Are Uncertain
Dec 10Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?
Oct 24Immunocore Holdings plc's (NASDAQ:IMCR) Business And Shares Still Trailing The Industry
Sep 19Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal
Aug 12Is Immunocore Holdings plc (NASDAQ:IMCR) Trading At A 33% Discount?
Jul 24Immunocore Holdings plc's (NASDAQ:IMCR) 28% Dip In Price Shows Sentiment Is Matching Revenues
Jun 16Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?
May 11Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
May 11Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?
Apr 05Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money
Jan 22Immunocore Holdings: Vulnerable To Profit Taking After Big Rally
Jan 21Revenues Not Telling The Story For Immunocore Holdings plc (NASDAQ:IMCR) After Shares Rise 37%
Dec 18Some Confidence Is Lacking In Immunocore Holdings plc's (NASDAQ:IMCR) P/S
May 08Forecast: Analysts Think Immunocore Holdings plc's (NASDAQ:IMCR) Business Prospects Have Improved Drastically
Nov 16Immunocore: Attractive Commercial-Stage Biopharma
Oct 05Need To Know: Analysts Are Much More Bullish On Immunocore Holdings plc (NASDAQ:IMCR)
Aug 12Immunocore GAAP EPS of -$0.17, revenue of $38.92M
Aug 10Immunocore to raise $140M in private placement financing
Jul 18Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 431 | -66 | 9 | 49 | 6 |
| 12/31/2026 | 376 | -103 | -34 | -50 | 11 |
| 12/31/2025 | 348 | -71 | -36 | -44 | 15 |
| 12/31/2024 | 308 | -43 | 21 | 20 | 15 |
| 9/30/2024 | 296 | -47 | 20 | 22 | N/A |
| 6/30/2024 | 281 | -55 | 9 | 11 | N/A |
| 3/31/2024 | 265 | -60 | -15 | -12 | N/A |
| 12/31/2023 | 249 | -55 | -2 | 3 | N/A |
| 9/30/2023 | 237 | -69 | 5 | 10 | N/A |
| 6/30/2023 | 220 | -61 | 6 | 12 | N/A |
| 3/31/2023 | 201 | -52 | -6 | -1 | N/A |
| 12/31/2022 | 174 | -53 | -51 | -49 | N/A |
| 9/30/2022 | 114 | -62 | -55 | -54 | N/A |
| 6/30/2022 | 82 | -112 | -96 | -94 | N/A |
| 3/31/2022 | 53 | -156 | -134 | -133 | N/A |
| 12/31/2021 | 36 | -180 | -144 | -143 | N/A |
| 9/30/2021 | 37 | -150 | -137 | -135 | N/A |
| 6/30/2021 | 39 | -139 | -111 | -110 | N/A |
| 3/31/2021 | 42 | -116 | -83 | -78 | N/A |
| 12/31/2020 | 41 | -101 | -88 | -84 | N/A |
| 9/30/2020 | 37 | -105 | -91 | -86 | N/A |
| 6/30/2020 | 34 | -109 | -137 | -131 | N/A |
| 3/31/2020 | 33 | -120 | -146 | -141 | N/A |
| 12/31/2019 | 34 | -138 | -142 | -136 | N/A |
| 12/31/2018 | 30 | -91 | -26 | -21 | N/A |
| 12/31/2017 | 19 | -66 | N/A | -82 | N/A |
| 12/31/2016 | 20 | -29 | N/A | -45 | N/A |
| 12/31/2015 | 17 | 20 | N/A | -26 | N/A |
| 9/30/2014 | 10 | -9 | N/A | 65 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IMCR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IMCR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IMCR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IMCR's revenue (16.7% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: IMCR's revenue (16.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IMCR is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 20:35 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Immunocore Holdings plc is covered by 22 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Peter Lawson | Barclays |
| Olga Smolentseva | Bryan Garnier & Co |